A global coalition set up to fight disease epidemics is investing up to $8.4 million to develop a synthetic vaccine system that could be tailor-made to fight multiple pathogens such as flu, Ebola, Marburg and rabies.

Changsheng Bio-technology Co. Ltd. – a vaccine maker at the center of a safety scandal in China – began falsifying production records for its rabies vaccine in April 2014, state news agency Xinhua reported.

The biotech industry did OK in July 2017. The NYSE ARCA Biotech Index and the iShares NASDAQ Biotechnology Index (ETF) grew about 1.9 percent and 2.9 percent, respectively last month. There have been 26 new molecular entity approvals so far this year. With that figure in mind, here are eight companies looking at PDUFA dates in August 2017.

A total of 202 people have been detained in connection with a scandal over an illegal black market vaccine ring, the Chinese government said on Wednesday, as it vowed to […]

An experimental vaccine offers total protection against Ebola, according to preliminary results from a large clinical trial. Among 4,000 vaccinated people, there were no cases of infection. The study concluded […]